Table 4.
Univariate analysis of study variables with modality choice as outcome
| Facility-based HD (n = 90) |
Self-care, Home HD or PD (n = 114) | P value | |
|---|---|---|---|
| TMT B, Median (IQR) | n = 64 102.0 (78.5–132.3) |
n = 93 90.0 (63.0–119.0) |
0.043a |
| TMT A, Median (IQR) | n = 83 49.0 (32.0–62.0) |
n = 110 42.0 (30.0–56.3) |
0.029a |
| 3MS, Median (IQR) | n = 85 93.0 (88.5–97.0) |
n = 108 94.5 (91.0–98.0) |
0.063a |
| MCQ1 (metamemory), Mean (SD) | n = 89 17.7 (3.8) |
n = 111 17.9 (3.7) |
0.61b |
| MCQ2 (metaconcentration), Mean (SD) | n = 88 13.9 (2.4) |
n = 110 14.9 (2.8) |
0.006b |
| Age, Mean (SD) | 62.6 (12.3) | 56.8 (13.1) | 0.001b |
| Gender, Female | 36 (40.0%) | 43 (37.7%) | 0.74c |
| Education, post-high school | 19/87 (21.8%) | 32/111 (28.8%) | 0.26c |
| Employment | |||
| Retired | 51 (56.7%) | 48 (42.1%) | |
| Unemployed | 19 (21.1%) | 20 (17.5%) | 0.022c |
| Salaried/self-employed | 20 (22.2%) | 46 (40.4%) | |
| Ethnicity, nonwhite | 12 (13.3%) | 8 (7.0%) | 0.13c |
| Marital status | |||
| Married or partner | 56 (62.2%) | 76 (66.7%) | |
| Single | 20 (22.2%) | 20 (17.5%) | 0.86c |
| Divorced or separated | 6 (6.7%) | 7 (6.1%) | |
| Widowed | 8 (8.9%) | 11 (9.6%) | |
| Cause of ESRD | |||
| Systemic | 50 (55.6%) | 42 (36.8%) | |
| Renal | 17 (18.9%) | 37 (32.5%) | 0.020c |
| Other/Unknown | 23 (25.6%) | 35 (30.7%) | |
| CCI, Median (IQR) | 5.0 (4.0–7.0) | 4.0 (3.0–6.0) | 0.003a |
| Diabetes | 32 (35.6%) | 32 (28.1%) | 0.25c |
| Heart failure | 4 (4.4%) | 5 (4.4%) | >0.99d |
| Ischaemic Heart Disease | 18 (20.0%) | 24 (21.1%) | 0.85c |
| IVE | 9 (10.0%) | 7 (6.1%) | 0.31c |
| Urea, Mean (SD) | n = 89 23.3 (7.7) |
n = 111 24.0 (6.6) |
0.51b |
| Creatinine – Median (IQR) | n = 89 377 (338–459) |
n = 111 428 (348–513) |
0.013a |
| Hb, <9 | 3/89 (3.4%) | 4/112 (3.6%) | >0.99d |
| Alb, <30 | 4/89 (4.5%) | 2/112 (1.8%) | 0.41d |
| Bic | n = 84 | n = 110 | |
| <22 | 37 (44.0%) | 49 (44.5%) | |
| 22–28 | 43 (51.2%) | 56 (50.9%) | 0.93e |
| >28 | 4 (4.8%) | 5 (4.5%) | |
| PTH, Median (IQR) | n = 86 23.6 (14.0–35.2) |
n = 112 25.2 (13.2–38.2) |
0.45a |
| Phosphate | n = 88 | n = 111 | |
| <1.1 | 11 (12.5%) | 13 (11.7%) | |
| 1.1–1.7 | 61 (69.3%) | 71 (64.0%) | 0.40e |
| >1.7 | 16 (18.2%) | 27 (24.3%) | |
| SBP, ≤115 | 4/89 (4.5%) | 10/112 (8.9%) | 0.22c |
| SBP, Mean (SD) | n = 89 143.7 (19.2) |
n = 112 138.4 (20.2) |
0.059b |
| DBP, >85 | 16/89 (18.0%) | 21/112 (18.8%) | 0.89c |
| DBP, Mean (SD) | n = 89 76.3 (11.1) |
n = 112 75.9 (11.6) |
0.81b |
| ACEI or ARB | 41 (45.6%) | 68/112 (60.7%) | 0.032c |
| Folic acid | 10 (11.1%) | 16/112 (14.3%) | 0.50c |
| Number of antihypertensive drugs, Median (IQR) | 3.0 (2.0–4.0) | n = 112 3.0 (2.0–4.0) |
>0.99a |
| EPO | 31 (34.4%) | 38/113 (33.6%) | 0.90c |
| CNS | 7 (7.8%) | 11/112 (9.8%) | 0.61c |
| Antidepressants | 18 (20.0%) | 13/112 (11.6%) | 0.10c |
| Antiplatelets | 39 (43.3%) | 37/112 (33.0%) | 0.13c |
| Statins/EZE | 53 (58.9%) | 65/112 (58.0%) | 0.90c |
| Pill burden, mean (SD) | 7.5 (2.6) | n = 112 7.3 (2.9) |
0.65b |
| BDI, median (IQR) | n = 82 12.0 (5.8–22.3) |
n = 98 7.5 (4.0–13.0) |
0.005a |
| STAI State, median (IQR) | n = 80 39.5 (29.3–47.8) |
n = 94 32.0 (26.0–42.3) |
0.010a |
| STAI Trait, median (IQR) | n = 79 41.0 (30.0–47.0) |
n = 91 35.0 (29.0–45.0) |
0.049a |
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCI, Charlson Comorbidity Index; CNS, central nervous system; DBP, diastolic blood pressure; EPO, erythropoeitin; ESRD, end-stage renal disease; EZE, ezetemibe; HD, hemodialysis; IQR, interquartile range; MCQI, Metacognition Questionnaire 1; PD, peritoneal dialysis; PTH, parathyroid hormone; SBP, systolic blood pressure; STAI, State and Trait Anxiety Inventory; 3MS, Modified Mini Mental State Examination.
a
Mann−Whitney U test.
b
Independent-samples t test.
c
Pearson χ2 test.
d
Fisher exact test.
e
χ2 linear trend test.